Fulgent Genetics Revenue Tops Estimates
Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.
Laboratory services and therapeutic development specialist Fulgent Genetics (NASDAQ:FLGT) delivered a standout performance in the fourth quarter, topping analysts' consensus estimates. On Friday, Feb. 28, the company reported adjusted EPS of $0.04, outstripping expectations of a $0.12 per-share loss. Q4 revenue climbed to $76.2 million, exceeding estimates of $74 million, marking an impressive annual growth of 8.1%.
Despite a GAAP earnings loss, the overall quarter showcased strength driven by a 14% increase in core revenue from its laboratory services segment.
Source: Fulgent Genetics. Note: Analyst consensus estimates for the quarter provided by FactSet. (YOY = Year over year.
